Weant Kyle A, Flynn Jeremy F, Akers Wendell S
University of North Carolina Hospitals and the School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Pharmacotherapy. 2006 Nov;26(11):1616-25. doi: 10.1592/phco.26.11.1616.
Antiplatelet therapy is commonly administered for primary and secondary prevention of stroke, recurrent angina, myocardial infarction, and death in patients with cardiovascular disorders. It also is associated with an increased risk of bleeding. We describe the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. In addition, we provide basic information about the mechanisms of action by which the most common antiplatelet agents inhibit platelet function. This information is integrated with results from pharmacologic studies and clinical trials. Determining the net effect in patients undergoing coronary artery bypass graft surgery requires knowledge about the pharmacokinetics, pharmacodynamics, and clinical efficacy of each drug, and an estimation of the absolute thrombotic versus hemorrhagic risk for each patient.
抗血小板治疗常用于心血管疾病患者中风、复发性心绞痛、心肌梗死及死亡的一级和二级预防。它也与出血风险增加相关。我们描述了冠状动脉旁路移植手术患者抗血小板治疗的管理。此外，我们提供了最常见抗血小板药物抑制血小板功能的作用机制的基本信息。这些信息与药理学研究和临床试验结果相结合。确定冠状动脉旁路移植手术患者的净效应需要了解每种药物的药代动力学、药效学和临床疗效，并估计每位患者的绝对血栓形成与出血风险。
